PTC Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- PTC Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Warren
- Headquarters state / province
- New Jersey
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- PTCT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001070081
- EIN
- 04-3416587
Board of directors
-
Alethia Young · DirectorSince 2023
-
Allan Steven Jacobson · DirectorSince 2023
-
David P. Southwell · DirectorSince 2023
-
Emma Reeve · DirectorSince 2023
-
Eric Pauwels · Director · CHIEF EXECUTIVE OFFICERSince 2024
-
Glenn Jr Md Steele Ph.D. · DirectorSince 2023
-
Hege Elisabeth Sollie-Zetlmayer · DirectorSince 2026
-
Jerome B. Zeldis · DirectorSince 2023
-
Jessica Caroline Chutter · DirectorSince 2026
-
Mary L. Smith · DirectorSince 2023
-
Matthew B. Klein · Director · CHIEF EXECUTIVE OFFICERSince 2023
-
Michael Schmertzler · DirectorSince 2023
-
Stephanie Okey · DirectorSince 2023
-
Stuart Walter Peltz · Director · CHIEF EXECUTIVE OFFICERSince 2023
-
William F. Bell Jr. · DirectorSince 2023
Chief executives
Matthew B. Klein
· CHIEF EXECUTIVE OFFICER
Dates unknown
Stuart Walter Peltz
· CHIEF EXECUTIVE OFFICER
Dates unknown
Eric Pauwels
· CHIEF EXECUTIVE OFFICER
Dates unknown
Director election results
Annual meeting of June 2, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
94.8%
-
96.1%
-
99.0%
Board connections
7 of this board's directors also sit on 10 other boards.
- via Matthew B. Klein
- via Emma Reeve
- via Michael Schmertzler
- via Jerome B. Zeldis
- via Alethia Young
- via David P. Southwell
- via Jerome B. Zeldis
- via David P. Southwell
- via Jessica Caroline Chutter
- via Emma Reeve
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $64,577,028
- 228 sales by 13 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 17, 2026 | Michael Schmertzler Director | Open-market sale | −9,624 | $67.83 | $652,796 |
| Sep 17, 2026 | Michael Schmertzler Director | Open-market sale | −376 | $68.45 | $25,737 |
| Sep 16, 2026 | Michael Schmertzler Director | Open-market sale | −2,994 | $66.58 | $199,341 |
| Sep 16, 2026 | Michael Schmertzler Director | Open-market sale | −7,006 | $67.35 | $471,854 |
| Sep 10, 2026 | Michael Schmertzler Director | Open-market sale | −10,000 | $67.34 | $673,400 |
| Sep 9, 2026 | Michael Schmertzler Director | Open-market sale | −9,428 | $67.79 | $639,124 |
| Sep 9, 2026 | Michael Schmertzler Director | Open-market sale | −572 | $68.67 | $39,279 |
| Aug 27, 2026 | Michael Schmertzler Director | Open-market sale | −11,890 | $71.55 | $850,730 |
| Aug 27, 2026 | Michael Schmertzler Director | Open-market sale | −610 | $72.22 | $44,054 |
| Aug 26, 2026 | Michael Schmertzler Director | Open-market sale | −6,874 | $72.74 | $500,015 |
| Aug 26, 2026 | Michael Schmertzler Director | Open-market sale | −5,626 | $73.18 | $411,711 |
| Aug 20, 2026 | Michael Schmertzler Director | Open-market sale | −9,419 | $70.78 | $666,677 |
| Aug 20, 2026 | Michael Schmertzler Director | Open-market sale | −2,390 | $71.88 | $171,793 |
| Aug 20, 2026 | Michael Schmertzler Director | Open-market sale | −691 | $72.92 | $50,388 |
| Aug 19, 2026 | Michael Schmertzler Director | Open-market sale | −5,335 | $72.86 | $388,708 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.